The interference of
azelastine with
pleurisy induced by
antigen was investigated in actively sensitized rats. The antigenic challenge (
ovalbumin, 12 micrograms/cavity) caused early plasma leakage, which peaked within 4 h, accompanied by intense neutrophil infiltration. Pleural exudate decayed 24 h after
antigen provocation, when a long-lasting increase in the number of resident eosinophils was observed. Oral pretreatment with
azelastine (1-10 mg/kg) dose dependently inhibited the vasopermeation (ED50 = 4.2 mg/kg) and reduced the pleural exudate (ED50 = 6.8 mg/kg) induced by the
antigen. In contrast,
azelastine (10 mg/kg) failed to modify the neutrophil influx observed at 4 h and the eosinophil accumulation detected at 24 h.
Azelastine was also effective against rat
pleurisy induced by either
platelet-activating factor (
PAF-acether),
histamine or
serotonin. It reduced exudation and the increase in the number of mononuclear cells, neutrophils and eosinophils observed 6 h after
PAF-acether. Nevertheless, antagonism of
PAF-acether may not be relevant to the inhibition observed in the present model of allergic
pleurisy, as the inhibition was refractory to three distinct
PAF-acether receptor antagonists. In contrast, like
azelastine, the
histamine H1 receptor antagonist meclizine and the dual
histamine and
serotonin receptor antagonist cyproheptadine blocked
antigen-induced exudation and failed to interfere with cell influx. We conclude that the anti-exudatory activity of oral
azelastine on
antigen-induced
pleurisy is consistent with it exerting direct effects against vasoactive
amines, but is not related to an effect against leucocyte infiltration nor to its ability to inhibit
PAF-acether.